Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Shu Li Guo"'
Autor:
Song-yun Wang, Wan-hua An, Ze-song Wang, Wan-li Wang, Bin Zhang, Kai-lin Xu, Shu-li Guo, Ming Gao, Bo Li, Lei Huang, Huan-huan Tian, Wen-yi Guo, Hui-rui Wang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for cancers, but reports on curing immune-related skin diseases are limited. We report a case of successful CAR-T-cell therapy in a patient with refractory/relapsed diffuse large B-c
Externí odkaz:
https://doaj.org/article/cbd3ad31ae3b457d9b71da7a769e3827
Publikováno v:
Jichu yixue yu linchuang, Vol 40, Iss 10, Pp 1369-1373 (2020)
Objective To investigate the effects of dehydrocostuslactone treatment on the proliferation and apoptosis of human HepG2 cells and potential mechanisms. Methods HepG2 cells were divided into 6 groups incubated with different concentration of Dehydroc
Externí odkaz:
https://doaj.org/article/0048c52bc7874fa1a65c85e002183562
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 6, Pp 731-738 (2016)
Objective: To review theories and technologies of big data mining and their application in clinical medicine. Data Sources: Literatures published in English or Chinese regarding theories and technologies of big data mining and the concrete applicati
Externí odkaz:
https://doaj.org/article/cb1412db5ed34e97bd1457d406a27738
Autor:
Chun-Xi Wang, Shu-Li Guo, Li-Na Han, Yang Jie, Hai-Di Hu, Jing-Ru Cheng, Miao Yu, Yue-Yong Xiao, Tai Yin, Fu-Tao Chu, Fa-Qi Liang
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 3, Pp 367-369 (2016)
Externí odkaz:
https://doaj.org/article/ce81bd0dd3384d78978869a90d54bad1
Publikováno v:
Bangladesh Journal of Pharmacology, Vol 11, Iss 3 (2016)
The primary objective of the current investigation was to study the anti-tumor effects of 5-methoxyhydnocarpin in THP-1 human leukemia cells along with evaluating its effects on apoptotic induction, cancer cell migration and cell cycle phase distribu
Externí odkaz:
https://doaj.org/article/f7dd8796f14b40e9993ff623b71c51ec
Autor:
Yongping Song, Lin Chen, Hongmiao Zhao, Yu-Lin Xu, Qing-Lin Song, Huirui Wang, Weiyong Li, Genjie Wang, Jingdong Li, Xiaomiao Ma, Ruihua Mi, Zhi-Chun Li, Zhanfang Wang, Qingsong Yin, Shu-Xia Chen, Xiaojiao Wang, Xudong Wei, Shu-Li Guo, Hai-Ping Yang
Objectives: This study investigated the therapeutic effects of combined recombinant human interferon-α-1b (IFN-α1b), thalidomide, and recombinant interleukin-2 (IL-2) in treating acute myeloid leukemia (AML) in patients of various disease status an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40e706fdf678c9516788f998a7602aba
https://doi.org/10.21203/rs.3.rs-562417/v1
https://doi.org/10.21203/rs.3.rs-562417/v1
Autor:
Xiao-yu Yin, Jin-Mei Li, Cheng-yin Ye, Jia-rui Xin, Li Wang, Tian-Yu Zhao, Shu-li Guo, Zheng Li, Lei Yang
Publikováno v:
Gene. 807
To investigate associations of genetic and environmental factors with coronary artery disease (CAD), we collected medical reports, lifestyle details, and blood samples of 2113 individuals, and then used the polymerase chain reaction (PCR)-ligase dete
Autor:
Rui-Hua, Mi, Lin, Chen, Ya-Lan, Zhou, Dong-Bei, Li, Sha, Liu, Xiao-Jiao, Wang, Jia, Liu, Min-Fang, Wang, Xiao-Miao, Ma, Zhi-Chun, Li, Hong-Mian, Zhao, Yu-Lin, Xu, Shu-Xia, Chen, Hai-Ping, Yang, Zhi-Qiang, Guo, Chun-Lai, Luan, Shu-Li, Guo, Qing-Lin, Song, Xu-Dong, Wei
Publikováno v:
Zhongguo shi yan xue ye xue za zhi. 29(1)
To explore the synergistic immunomodulatory mechanism of interferon alpha-1b, interleukin-2 and thalidomide (ITI) regimen on patients with acute myeloid leukemia (AML).Sixty eight untreated de novo or relapsed or refractory or maintenance therapy pat
Publikováno v:
Zhongguo shi yan xue ye xue za zhi. 28(3)
To retrospectively analyze the identification results of irregular antibodies, to clarify the distribution features and to explore the relation of alloantibodies and autoantibodies with the immunized history of patients and disease kinds.49 820 patie
Publikováno v:
Medicine
Background: Over the past years, ixazomib has been increasingly explored for the treatment of relapsed/refractory multiple myeloma (RRMM). However, its results are still contradictory. This study will explore the efficacy and safety of ixazomib for p